Esperion Therapeutics (ESPR) Tops Q2 EPS by 15c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/14/2026
- Wall Street ends higher as SpaceX's market debut dominates
- SpaceX prices historic IPO at $135/share in largest ever new listing
- 'Ocean of opportunity': Wolfe initiates SpaceX at Buy ahead of historic IPO
- UBS cuts gold price forecasts on delayed Fed easing outlook
- Brent falls to lowest since March on expected peace deal
- NASDAQ adds five companies to NASDAQ-100 index in quarterly rebalance
- Super Micro Computer establishes $1.25 billion stock sale agreement
- Wall Street ends higher as SpaceX's market debut dominates
- 'Ocean of opportunity': Wolfe initiates SpaceX at Buy ahead of historic IPO
- SpaceX Shares Indicated To Open At $155
Northland Upgrades Esperion Therapeutics (ESPR) to Market Perform. 'Potential Resolution of DSE Litigation as Catalysts'
August 1, 2023 2:01 PM EDTNorthland Capital Markets analyst Carl Byrnes upgraded Esperion Therapeutics (NASDAQ: ESPR) from Underperform to Market Perform with a price target of $2.00 (from $1.00).
The analyst comments "We are adjusting our rating to MP as we believe sNDA approvals in both the... More
